Feeds:
Posts
Comments

Posts Tagged ‘organic synthesis’


newly developed oxazolidinone antibiotics

Larry H. Bernstein, MD, FCAP, Curator

LPBI

 

 

New Antibacterial oxazolidinones in pipeline by Wockhardt

by DR ANTHONY MELVIN CRASTO Ph.D

 

WCK ?

(5S)-N-{3-[3,5-difluoro-4-(4-hydroxy-4-methoxymethyl-piperidin-1-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide

MF C19 H25 F2 N3 O5, MW 413.42

Acetamide, N-​[[(5S)​-​3-​[3,​5-​difluoro-​4-​[4-​hydroxy-​4-​(methoxymethyl)​-​1-​piperidinyl]​phenyl]​-​2-​oxo-​5-​oxazolidinyl]​methyl]​-

CAS 957796-51-9

Antibacterial oxazolidinones

THIS MAY BE WCK 4086?????

PATENT

WO 2015173664, US8217058, WO 2012059823, 

 

Oxazolidinone represent a novel chemical class of synthetic antimicrobial agents.Linezolid represents the first member of this class to be used clinically. Oxazolidinones display activity against important Gram-positive human and veterinary pathogens including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE) and β-lactam Resistant Streptococcus pneumoniae (PRSP). The oxazolidinones also show activity against Gram-negative aerobic bacteria, Gram-positive and Gram-negative anaerobes. (Diekema D J et al., Lancet 2001 ; 358: 1975-82).

Various oxazolidinones and their methods of preparation are disclosed in the literature. International Publication No. WO 1995/25106 discloses substituted piperidino phenyloxazolidinones and International Publication No. WO 1996/13502 discloses phenyloxazolidinones having a multisubstituted azetidinyl or pyrrolidinyl moiety. US Patent Publication No. 2004/0063954, International Publication Nos. WO 2004/007489 and WO 2004/007488 disclose piperidinyl phenyl oxazolidinones for antimicrobial use.

Pyrrolidinyl/piperidinyl phenyl oxazohdinone antibacterial agents are also described in Kim H Y et al., Bioorg. & Med. Chem. Lett., (2003), 13:2227-2230. International Publication No. WO 1996/35691 discloses spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinone derivatives. Diazepeno phenyloxazolidinone derivatives are disclosed in the International Publication No. WO 1999/24428. International Publication No. WO 2002/06278 discloses substituted aminopiperidino phenyloxazolidinone derivatives.

Various other methods of preparation of oxazolidinones are reported in US Patent No. 7087784, US Patent No. 6740754, US Patent No. 4948801 , US Patent No. 3654298, US Patent No. 5837870, Canadian Patent No. 681830, J. Med. Chem., 32, 1673 (1989), Tetrahedron, 45, 1323 (1989), J. Med. Chem., 33, 2569 (1990), Tetrahedron Letters, 37, 7937-40 (1996) and Organic Process Research and Development, 11 , 739-741(2007).

Indian Patent Application No. 2534/MUM/2007 discloses a process for the preparation of substituted piperidino phenyloxazolidinones. International Publication No. WO2012/059823 further discloses the process for the preparation of phosphoric acid mono-(L-{4-[(5)-5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2,6-difluorophenyl}4-methoxymethyl piperidine-4-yl)ester.

US Patent No. 8217058 discloses (5S)-N-{3-[3,5-difluoro-4-(4-hydroxy-4-methoxymethyl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide as an antibacterial agent and its process for preparation.

PATENT

WO2015173664

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015173664&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription

 

 

PATENT

http://www.google.st/patents/WO2007132314A2?cl=en

 

Figure imgf000004_0001

Wockhardt Ltd,

Figure imgf000006_0001
Figure imgf000006_0002

(3) (4)

 

PATENT

WO 2012059823

http://www.google.co.in/patents/WO2012059823A1?cl=en

Phosphoric acid mono-(l-{4-[(S)-5-(acetylamino- methyl)-2-oxo-oxazolidin-3-yl]-2,6-difluorophenyl}-4-methoxymethyl-piperidin-4-yl) ester of Formula (A),
Figure imgf000022_0001
the process comprising the steps of:
a) Converting intermediate of Formula (1) into intermediate of Formula (3)
Figure imgf000022_0002
b) Converting intermediate of Formula (3) into intermediate of Formula (5)
Figure imgf000022_0003

c) Converting intermediate of Formula (5) into intermediate of structure (6)

Figure imgf000022_0004
(5) <6> d) Converting intermediate of Formula (6) into intermediate of Formula (10)
Figure imgf000023_0001
e) Converting intermediate of Formula (10) into intermediate of Formula (11),
Figure imgf000023_0002

f) Converting intermediate of Formula (11) into compound of Formula (A) or Pharmaceutically acceptable salts thereof

Figure imgf000023_0003

 

 

Figure imgf000006_0001
Figure imgf000006_0002
Figure imgf000006_0003

 

Read Full Post »


assembling biomolecules

Larry H. Bernstein, MD, FCAP, Curator

LPBI

 

 

A powerful new ‘tool’ for assembling biomolecules

Replaces the existing expensive and complex process needed when synthesizing new chemicals — could revolutionize pharmaceutical and biomaterials manufacturing
October 21, 2015

http://www.kurzweilai.net/a-powerful-new-tool-for-assembling-biomolecules?utm_source=KurzweilAI+Weekly+Newsletter_147a5a48c1-9a20162408-282099089

 

Proposed new simplified chemical reaction for assembling biomolecules in a single chemical reaction (credit: Tiffany Piou & Tomislav Rovis/Nature)

 

Colorado State University chemists have invented a single chemical reaction that couples two constituent chemicals into a carbon-carbon bond, while simultaneously introducing a nitrogen component. The process promises to replace a multi-step, expensive, and complex process needed when synthesizing new chemicals — for drug creation and testing, for example.

The researchers were able to control this reaction to make the nitrogen atoms go exactly where they want them to, making for precision chemistry that they believe could revolutionize pharmaceutical and biomaterials manufacturing.

The achievement is detailed in the journal Nature, published today (Oct. 21).

Achieving a critical carbon-nitrogen bond

The researchers explain in a statement that “almost every significant carbon-based biomolecule contains a nitrogen compound, or amine. Achieving this carbon-nitrogen bond in the lab, though, is tricky business. Drug companies know it well…. They must first create the carbon-carbon bonds, and then introduce the nitrogen to make a molecule that will do something useful.”

The chemists’ starting materials were simply oil refinery byproducts called olefins, or alkenes. They mixed in a specially engineered reagant, then used a complex based on the precious metal rhodium to reliably and specifically trigger the elusive carbon-nitrogen bonds.

The innovation also controls molecular isomers (an isomer is a molecule with the same chemical formula as another molecule, but with a different chemical structure). Some isomers are mirror images, like right and left gloves, and although they’re chemically identical, their functionalities are strikingly different. Being able to select for a single isomer is critical to safety and efficacy — so much so that the FDA mandates that only single-isomer drugs be marketed for human use.

Take thalidomide, infamous for causing severe birth defects when taken by pregnant women in the 1950s. Chemically, thalidomide comes in two mirror-image isomeric forms. One caused the defects, one didn’t.

“For this reason, spatial display of groups in molecules is incredibly important,” said organic chemist Tomislav Rovis, professor of chemistry in the College of Natural Sciences at CSU. Rovis led the research with postdoctoral researcher Tiffany Piou, who designed all the chemical building blocks and ran the experiments.

“Tiffany’s finding gives us a leg up to do this in a carboamination reaction, by making the carbon carbon bond, and delivering the nitrogen selectively,” Rovis said.

The researchers hope their approach, which they liken to a tool in a toolbox, can be polished, perfected and used widely to make organic chemistry easier, and applied to many different fields.


Abstract of Rhodium-catalysed syn-carboamination of alkenes via a transient directing group

Alkenes are the most ubiquitous prochiral functional groups—those that can be converted from achiral to chiral in a single step—that are accessible to synthetic chemists. For this reason, difunctionalization reactions of alkenes (whereby two functional groups are added to the same double bond) are particularly important, as they can be used to produce highly complex molecular architectures12. Stereoselective oxidation reactions, including dihydroxylation, aminohydroxylation and halogenation3456, are well established methods for functionalizing alkenes. However, the intermolecular incorporation of both carbon- and nitrogen-based functionalities stereoselectively across an alkene has not been reported. Here we describe the rhodium-catalysed carboamination of alkenes at the same (syn) face of a double bond, initiated by a carbon–hydrogen activation event that uses enoxyphthalimides as the source of both the carbon and the nitrogen functionalities. The reaction methodology allows for the intermolecular, stereospecific formation of one carbon–carbon and one carbon–nitrogen bond across an alkene, which is, to our knowledge, unprecedented. The reaction design involves the in situ generation of a bidentate directing group and the use of a new cyclopentadienyl ligand to control the reactivity of rhodium. The results provide a new way of synthesizing functionalized alkenes, and should lead to the convergent and stereoselective assembly of amine-containing acyclic molecules.

Read Full Post »